Lilly Eli Co (LLY)

Lilly (Eli) & Co Stock (LLY) dropped by 3.65% from $610.82 to $588.54 in the trading on Wednesday November 15, 2023. The reason why LLY stock down today is due to the news of factory expansion. Reuters reported that Lilly aims to build a new facility in Western Germany that will cost in the single-digit, billion-dollar range. Eli Lilly's plan to spend a hefty chunk of its cash (up to 42%) on a new German factory, spooked investors despite Mounjaro's weight loss approval. The billion-dollar price tag seems to outweigh the potential boost to Zepbound production.

Lilly (Eli) & Co Stock (LLY) dropped by 4.49% from $619.13 to $591.32 in the trading on Thursday November 09, 2023. The reason why LLY stock down today is due to the news of weight loss drug approval. Eli Lilly (LLY) shares tumbled after FDA approval of tirzepatide (Zepbound) for weight loss, despite the positive news. Investors likely followed the "buy the rumor, sell the news" strategy, taking profits after the long-awaited approval, especially with LLY's 60% year-to-date surge. While a short-term dip, it doesn't overshadow Lilly's overall strong performance.

Lilly (Eli) & Co Stock (LLY) dropped by 2.43% from $538.29 to $525.19 in the trading on Tuesday October 03, 2023. The reason why LLY stock down today is due to the news of Point Biopharma Globa acquisition. Eli Lilly's cancer ambitions stumbled as investors slammed their $1.4 billion Point Biopharma buy. Despite the lucrative cancer market and Alimta's success, Lilly's stock tanked 2.4%, suggesting investors see Point as a sign they're still far from oncology dominance. The hefty price tag and Point's lackluster performance might have left investors yearning for a more impactful move.

Eli Lilly & Co. (LLY, -0.49%) witnessed a slight decline in its share price, dropping by 0.5% following the announcement of its deal to sell its Baqsimi hypoglycemia treatment for individuals with diabetes to Amphastar Pharmaceuticals Inc.

Lilly (Eli) & Co Stock (LLY) dropped by 3.46% from $342.57 to $330.70 in the trading on Thursday February 02, 2023. The reason why LLY stock down today is due to its 2022 fourth-quarter financial results. Eli Lilly's global Q4 revenue experienced a significant 9% decline compared to the same period last year. This downturn was driven by a confluence of negative factors, including:

• Currency headwinds: A robust US dollar eroded the value of overseas sales.
• COVID-19 antibody decline: Sales of COVID-19 antibody treatments plummeted by 96% year-over-year, reflecting waning pandemic demand.
• Alimta exclusivity loss: The expiration of patent exclusivity for cancer drug Alimta led to increased competition and lower revenue.
• Mounjaro sales shortfall: Sales of the diabetes drug Mounjaro fell short of expectations, contributing to the overall revenue decline.

Lilly (Eli) & Co Stock (LLY) dropped by 1.43% from $251.08 to $346.07 in the trading on Friday January 20, 2023. The reason why LLY stock down today is due to the news of FDA rejection of its Alzheimer's treatment. Eli Lilly's Alzheimer's drug donanemab took a hit after the FDA rejected its accelerated approval request. Donanemab removes beta amyloid plaques like Biogen's approved drugs, but its fast action had some patients off it after six months. The FDA wants at least a year of data, so Lilly awaits final study results before traditional approval, leaving investors waiting until Q2.